IL158780A0 - Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis - Google Patents
Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosisInfo
- Publication number
- IL158780A0 IL158780A0 IL15878002A IL15878002A IL158780A0 IL 158780 A0 IL158780 A0 IL 158780A0 IL 15878002 A IL15878002 A IL 15878002A IL 15878002 A IL15878002 A IL 15878002A IL 158780 A0 IL158780 A0 IL 158780A0
- Authority
- IL
- Israel
- Prior art keywords
- thrombosis
- prevention
- treatment
- receptor antagonist
- another anti
- Prior art date
Links
- 208000007536 Thrombosis Diseases 0.000 title 1
- 239000003146 anticoagulant agent Substances 0.000 title 1
- 229960004676 antithrombotic agent Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101932A SE0101932D0 (sv) | 2001-05-31 | 2001-05-31 | Pharmaceutical combinations |
PCT/SE2002/001033 WO2002096428A1 (en) | 2001-05-31 | 2002-05-29 | Pharmaceutical combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
IL158780A0 true IL158780A0 (en) | 2004-05-12 |
Family
ID=20284321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15878002A IL158780A0 (en) | 2001-05-31 | 2002-05-29 | Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis |
Country Status (24)
Country | Link |
---|---|
US (2) | US20040146498A1 (pl) |
EP (1) | EP1397139A1 (pl) |
JP (1) | JP2004532869A (pl) |
KR (1) | KR20040003029A (pl) |
CN (1) | CN100352442C (pl) |
AR (1) | AR034343A1 (pl) |
AU (1) | AU2002305952B2 (pl) |
BR (1) | BR0210034A (pl) |
CA (1) | CA2447648A1 (pl) |
CO (1) | CO5550445A2 (pl) |
CZ (1) | CZ20033246A3 (pl) |
EE (1) | EE200300589A (pl) |
HU (1) | HUP0400069A3 (pl) |
IL (1) | IL158780A0 (pl) |
IS (1) | IS7051A (pl) |
MX (1) | MXPA03010761A (pl) |
NO (1) | NO20035315D0 (pl) |
PL (1) | PL366510A1 (pl) |
RU (1) | RU2331422C2 (pl) |
SE (1) | SE0101932D0 (pl) |
SK (1) | SK14732003A3 (pl) |
TW (1) | TWI232751B (pl) |
WO (1) | WO2002096428A1 (pl) |
ZA (1) | ZA200308780B (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867199B2 (en) | 2000-08-21 | 2005-03-15 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapeutic use |
JP2004346067A (ja) * | 2003-04-28 | 2004-12-09 | Mitsubishi Pharma Corp | 抗血栓薬の治療可能時間を延長するための薬剤 |
JP2007509180A (ja) | 2003-10-21 | 2007-04-12 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 疼痛を治療するための、非ヌクレオチド組成物および方法 |
US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
ATE469157T1 (de) | 2003-10-21 | 2010-06-15 | Inspire Pharmaceuticals Inc | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation |
US7749981B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
US7504497B2 (en) | 2003-10-21 | 2009-03-17 | Inspire Pharmaceuticals, Inc. | Orally bioavailable compounds and methods for inhibiting platelet aggregation |
WO2006045756A1 (en) * | 2004-10-25 | 2006-05-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
US7932376B2 (en) | 2005-05-05 | 2011-04-26 | Inspire Pharmaceuticals, Inc. | Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation |
US9532945B2 (en) * | 2006-04-04 | 2017-01-03 | Kg Acquisition Llc | Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor |
JP2010508350A (ja) * | 2006-10-31 | 2010-03-18 | ヤンセン ファーマシューティカ エヌ.ベー. | Adpp2y12レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体 |
UA100864C2 (uk) * | 2007-12-03 | 2013-02-11 | Астразенека Аб | Спосіб лікування або запобігання аневризмі черевної аорти |
JP5635617B2 (ja) * | 2009-11-09 | 2014-12-03 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Pnhii型白血球を検出するための試薬および方法、ならびに血栓障害の危険因子としてのそれらの同定 |
WO2011067571A1 (en) * | 2009-12-03 | 2011-06-09 | Astrazeneca Ab | Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor |
EP2515871B1 (en) | 2009-12-23 | 2015-09-23 | ratiopharm GmbH | Solid pharmaceutical dosage form of ticagrelor |
WO2011076401A1 (de) | 2009-12-23 | 2011-06-30 | Holger Schankin | Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen |
CN102653539B (zh) * | 2011-03-01 | 2014-09-17 | 秦引林 | 一种抗血小板聚集化合物及其药物组合 |
MX2013014035A (es) * | 2011-06-01 | 2014-01-23 | Astrazeneca Ab | Nuevo co-cristal ticagrelor. |
US20160120869A1 (en) * | 2013-05-29 | 2016-05-05 | Ratiopharm Gmbh | Solid pharmaceutical dosage form |
CN104277039B (zh) * | 2014-09-19 | 2016-06-01 | 广东东阳光药业有限公司 | 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途 |
WO2016116942A1 (en) * | 2015-01-20 | 2016-07-28 | Anlon Chemical Research Organization | Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin |
WO2016120729A1 (en) * | 2015-01-27 | 2016-08-04 | Astrazeneca Ab | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
CN106204544B (zh) * | 2016-06-29 | 2019-04-05 | 南京中观软件技术有限公司 | 一种自动提取图像中标志点位置及轮廓的方法和*** |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9404196D0 (sv) * | 1994-12-02 | 1994-12-02 | Astra Ab | New antithrombotic formulation |
EE03616B1 (et) * | 1995-07-11 | 2002-02-15 | Astra Pharmaceuticals Limited | Uued vereliistakute agregatsiooni pärssivad ained |
TWI238827B (en) * | 1995-12-21 | 2005-09-01 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
FR2744918B1 (fr) * | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
TWI229674B (en) * | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
KR20020005614A (ko) * | 1999-03-11 | 2002-01-17 | 블레어 큐. 퍼거슨 | Xa 인자 저해제와 아스피린, 조직 플라스미노겐활성화인자(TPA), GPⅡb/Ⅲa 길항제, 저분자량헤파린 또는 헤파린의 병용에 의한 혈전증 치료 |
AR023510A1 (es) * | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
-
2001
- 2001-05-31 SE SE0101932A patent/SE0101932D0/xx unknown
-
2002
- 2002-05-20 TW TW091110514A patent/TWI232751B/zh not_active IP Right Cessation
- 2002-05-24 AR ARP020101955A patent/AR034343A1/es not_active Application Discontinuation
- 2002-05-29 US US10/479,019 patent/US20040146498A1/en not_active Abandoned
- 2002-05-29 CN CNB028109120A patent/CN100352442C/zh not_active Expired - Fee Related
- 2002-05-29 EP EP02733751A patent/EP1397139A1/en not_active Withdrawn
- 2002-05-29 SK SK1473-2003A patent/SK14732003A3/sk not_active Application Discontinuation
- 2002-05-29 MX MXPA03010761A patent/MXPA03010761A/es not_active Application Discontinuation
- 2002-05-29 CZ CZ20033246A patent/CZ20033246A3/cs unknown
- 2002-05-29 PL PL02366510A patent/PL366510A1/pl not_active Application Discontinuation
- 2002-05-29 JP JP2002592938A patent/JP2004532869A/ja active Pending
- 2002-05-29 WO PCT/SE2002/001033 patent/WO2002096428A1/en active IP Right Grant
- 2002-05-29 CA CA002447648A patent/CA2447648A1/en not_active Abandoned
- 2002-05-29 EE EEP200300589A patent/EE200300589A/xx unknown
- 2002-05-29 RU RU2003133216/15A patent/RU2331422C2/ru not_active IP Right Cessation
- 2002-05-29 BR BR0210034-7A patent/BR0210034A/pt not_active IP Right Cessation
- 2002-05-29 HU HU0400069A patent/HUP0400069A3/hu unknown
- 2002-05-29 KR KR10-2003-7015565A patent/KR20040003029A/ko not_active Application Discontinuation
- 2002-05-29 AU AU2002305952A patent/AU2002305952B2/en not_active Ceased
- 2002-05-29 IL IL15878002A patent/IL158780A0/xx unknown
-
2003
- 2003-11-11 ZA ZA200308780A patent/ZA200308780B/en unknown
- 2003-11-26 IS IS7051A patent/IS7051A/is unknown
- 2003-11-28 CO CO03105239A patent/CO5550445A2/es not_active Application Discontinuation
- 2003-11-28 NO NO20035315A patent/NO20035315D0/no not_active Application Discontinuation
-
2006
- 2006-04-17 US US11/406,746 patent/US20060189584A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20035315D0 (no) | 2003-11-28 |
BR0210034A (pt) | 2004-08-10 |
EE200300589A (et) | 2004-02-16 |
WO2002096428A1 (en) | 2002-12-05 |
ZA200308780B (en) | 2005-02-11 |
US20040146498A1 (en) | 2004-07-29 |
AR034343A1 (es) | 2004-02-18 |
CZ20033246A3 (cs) | 2004-02-18 |
MXPA03010761A (es) | 2004-03-02 |
TWI232751B (en) | 2005-05-21 |
IS7051A (is) | 2003-11-26 |
CO5550445A2 (es) | 2005-08-31 |
US20060189584A1 (en) | 2006-08-24 |
HUP0400069A3 (en) | 2006-02-28 |
HUP0400069A2 (hu) | 2004-04-28 |
RU2003133216A (ru) | 2005-04-20 |
CN1512885A (zh) | 2004-07-14 |
SE0101932D0 (sv) | 2001-05-31 |
CA2447648A1 (en) | 2002-12-05 |
CN100352442C (zh) | 2007-12-05 |
PL366510A1 (pl) | 2005-02-07 |
EP1397139A1 (en) | 2004-03-17 |
RU2331422C2 (ru) | 2008-08-20 |
JP2004532869A (ja) | 2004-10-28 |
AU2002305952B2 (en) | 2007-08-09 |
KR20040003029A (ko) | 2004-01-07 |
SK14732003A3 (sk) | 2004-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL158780A0 (en) | Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis | |
HK1066466A1 (en) | Pharmaceutical formulations of antineoplastic agents in particular temozolomide processes of making and using the same | |
IL161110A0 (en) | Prevention and treatment of restenosis by local admistration of drug | |
PL359862A1 (pl) | Benzofenony jako inhibitory IL-1beta i TNF-alfa | |
IL211288A0 (en) | Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility | |
HUP0400248A3 (en) | Mch antagonists pharmaceutical compositions containing them and their use in the treatment of obesity | |
GB0111872D0 (en) | Therapeutic agents and methods | |
HUP0303927A3 (en) | Combination therapy using anti-angiogenic agents and tnf-alpha | |
IL149495A0 (en) | Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy | |
EP1350431A4 (en) | METHOD FOR SELECTING AN ANTIMICROBIAL AGENT AND METHOD OF USING THE SAME | |
GB0108470D0 (en) | Pharmaceutical compositions and their use | |
GB0105613D0 (en) | Pharmaceutically effective compounds and their use | |
IL156506A0 (en) | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof | |
GB0119025D0 (en) | Compounds and their therapeutic use | |
HUP0303612A3 (en) | Bicyclic guanidine derivatives and their therapeutic use | |
EP1371371A4 (en) | USE OF N-ACETYL-D-GLUCOSAMINE IN THE PRODUCTION OF A PHARMACEUTICAL AGENT FOR THE PREVENTION AND TREATMENT OF SEXUAL DISORDERS | |
GB0119370D0 (en) | Therapeutic agent | |
EP1557169A4 (en) | THERAPEUTIC AND / OR PROPHYLACTIC AGENT FOR DYSCHEZIA | |
EP1392460A4 (en) | AMINOSILANOL HYDROFLUORIDES AND THEIR USE | |
GB2376943B (en) | Compounds and their therapeutic use | |
GB0112237D0 (en) | Compounds and their therapeutic use | |
HUP0401041A3 (en) | Use an inhibitor of the renin-angiotensin system for the treatment of lipodystrophy the preparation pharmaceutical composition using in | |
IL152931A0 (en) | BENZOPHENONES AS INHIBITORS OF IL-1beta AND TNF-alpha | |
GB0125210D0 (en) | Therapeutic agent | |
GB0108589D0 (en) | Therapeutic agent |